CYDY Stock Falls Despite Positive Cancer Study Data – Retail Says CytoDyn Is ‘Here To Stay’

•  The study evaluated Leronlimab, an investigational antibody, in combination with standard therapies TAS-102 and Bevacizumab, a targeted therapy that blocks tumor growth.
• The study showed positive results for Leronlimab in combination with other therapies, supporting CCR5 as a promising treatment target.
• In a subset of patients, tumor DNA levels dropped by about 70% within two weeks.

CytoDyn Inc. (CYDY) shares were in the spotlight on Wednesday after the biotech firm reported encouraging early data from an ongoing study of its treatment for metastatic colorectal cancer.

At the time of writing, CYDY shares were trading 5% lower.

Leronlimab Shows Promise Against Tumor Growth

The study, presented at the AACR Annual Meeting, evaluated Leronlimab, an investigational antibody, in combination with standard therapies TAS-102 and Bevacizumab, a targeted therapy that blocks tumor growth. Early findings showed promising clinical and biomarker activity, particularly in heavily pretreated patients.

CCR5 protein was found in all 33 patients in the study, suggesting it is common in metastatic colorectal cancer and could be a good target for new treatments. The study showed that blocking CCR5 with Leronlimab may help change the environment around the tumor and boost the immune response.

In a subset of patients, tumor DNA levels dropped by about 70% within two weeks, indicating a rapid response to treatment. The combination therapy also showed a favorable safety profile, with no major dose-limiting side effects. The trial is ongoing and continues to enroll patients, CytoDyn added.

“The early biomarker and clinical signals observed in our ongoing Phase 2 mCRC study reinforce the potential of leronlimab-based combination approaches to enhance immune engagement and address resistance in heavily pretreated patients,” said CEO Jacob P. Lalezari.

How Did Retail Traders React?

Despite the intraday decline, retail sentiment on Stocktwits remained ‘extremely bullish’ over the past 24 hours, amid ‘extremely high’ message volumes.

One bullish user said, “CYDY and Leronlimab are here to stay in the fight against cancer.”

Another user hoped for a positive response from the FDA.

The stock has gained more than 14% so far this year.

For updates and corrections, email newsroom[at]stocktwits[dot]com.